Using ctDNA to Monitor Patients With Lung Cancers

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Chrisitian Rolfo, MD, PhD, Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, discussed the use of ctDNA to monitor patients with lung cancers.

Transcript:

Hello, my name is Christian Rolfo and I'm a Professor of Medicine at the Icahn School of Medicine in New York, New York, and the Associate Director for Clinical Research at the Center of Thoracic Oncology at the Tisch Cancer Institute at Mount Sinai in New York. I was recently represented in Great Debates & Updates in Lung Cancer in New York and our session was discussing on biomarkers.

Specifically in my presentation, I spoke about the possibility of monitoring patients using ctDNA. We know liquid biopsy was entering recently in the scenario of landscape of lung cancer in different new applications so, we started to accumulate several of the evidence in metastatic setting and nowadays we are using specifically also in a new scenario, like minimal residual disease or even in screening. The possibility to tailor the treatment of patients was seen already in targeted therapies. We started with the identification of the biomarkers and then mechanism of resistance and nowadays we can actually see the response assessments with the liquid biopsy.

In the last 2 years, we have an evolution also or revolution in the area of the immunotherapy, specifically using ctDNA, and we start to accumulate several evidence of utility of liquid biopsy in this field, specifically in advanced disease. And one of the most important advances was the use of dynamics of ctDNA, that is very important because that will open the door for new kinds of trials with escalation or deescalation that are actually running at this moment, so very exciting times for liquid biopsy.

We were discussing also the opportunity to include as a surrogate of also response in pathological complete response in neoadjuvant setting. We have a very good discussion and I hope that you can enjoy on demand all this content from these great debates in New York, and we hope that you can join us in the next Great Debates & Updates in Lung Cancer that would be virtually. Thank you very much.

Source:

Rolfo C. Serial Monitoring Using Liquid Biopsy. Presented at Great Debates & Updates in Lung Cancer; September 21-23. New York, NY.